Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AstraZeneca PLC stock logo
AZN
AstraZeneca
$75.17
+0.2%
$67.27
$60.47
$75.81
$233.06B0.55.72 million shs6.69 million shs
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
$1.92
-1.5%
$2.45
$1.42
$10.88
$100.59M1.2970,678 shs880,929 shs
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
$3.80
-1.8%
$6.66
$1.63
$8.83
$432.50M1.662.13 million shs2.73 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$146.14
-0.5%
$155.26
$143.13
$175.97
$352.17B0.537.73 million shs6.18 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$107.97
+1.7%
$102.54
$62.55
$142.79
$41.34B1.622.94 million shs2.25 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.40
+0.6%
$26.96
$25.20
$40.37
$143.83B0.6134.12 million shs46.53 million shs
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$495.35
+0.3%
$485.84
$436.38
$554.70
$455.76B0.545.62 million shs2.73 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AstraZeneca PLC stock logo
AZN
AstraZeneca
0.00%+9.66%+10.95%+12.03%+2.06%
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
-0.26%-5.88%-24.26%+5.49%-78.64%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
0.00%-20.67%-48.23%-16.67%-34.71%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+0.01%-1.20%-7.61%-8.38%-10.13%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%+6.47%+1.32%+6.05%-17.40%
Pfizer Inc. stock logo
PFE
Pfizer
+0.08%-2.31%-8.47%-7.54%-34.25%
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
0.00%-1.15%+0.13%-1.56%+2.57%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AstraZeneca PLC stock logo
AZN
AstraZeneca
1.8661 of 5 stars
1.33.01.70.02.50.03.1
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
3.8817 of 5 stars
3.02.00.04.61.81.71.3
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
4.1987 of 5 stars
4.01.00.04.71.72.50.6
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
4.9366 of 5 stars
3.23.04.23.93.82.51.9
Moderna, Inc. stock logo
MRNA
Moderna
4.026 of 5 stars
3.12.00.04.61.83.30.6
Pfizer Inc. stock logo
PFE
Pfizer
4.9751 of 5 stars
3.23.04.24.83.01.73.1
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
4.9759 of 5 stars
3.43.04.24.03.62.52.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AstraZeneca PLC stock logo
AZN
AstraZeneca
2.57
Moderate Buy$81.007.76% Upside
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
2.00
Hold$5.00160.42% Upside
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
2.08
Hold$6.7377.03% Upside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.46
Hold$175.8620.33% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.25
Hold$126.4917.15% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.38
Hold$36.3343.04% Upside
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
2.83
Moderate Buy$570.0515.08% Upside

Current Analyst Ratings

Latest JNJ, UNH, PFE, MRNA, EBS, AZN, and FATE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/26/2024
AstraZeneca PLC stock logo
AZN
AstraZeneca
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$80.00 ➝ $82.00
4/23/2024
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$7.00
4/19/2024
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$545.00 ➝ $562.00
4/18/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$169.00 ➝ $170.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$168.00 ➝ $167.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$180.00 ➝ $170.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$181.00 ➝ $175.00
4/17/2024
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$566.00 ➝ $571.00
4/17/2024
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$534.00 ➝ $560.00
4/17/2024
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$596.00 ➝ $555.00
4/17/2024
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$600.00
(Data available from 4/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AstraZeneca PLC stock logo
AZN
AstraZeneca
$45.81B5.09$5.40 per share13.93$12.63 per share5.95
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
$1.02B0.10$0.88 per share2.18$12.51 per share0.15
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
$63.53M6.81N/AN/A$3.74 per share1.02
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$81.80B4.31$13.67 per share10.69$28.57 per share5.12
Moderna, Inc. stock logo
MRNA
Moderna
$6.85B6.04N/AN/A$36.33 per share2.97
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.46$2.98 per share8.53$15.81 per share1.61
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$379.49B1.20$29.77 per share16.64$100.39 per share4.93

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AstraZeneca PLC stock logo
AZN
AstraZeneca
$5.96B$2.0436.8516.131.3813.30%30.34%11.75%7/26/2024 (Estimated)
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
-$760.50M-$14.83N/AN/AN/A-72.11%-37.35%-14.81%5/1/2024 (Confirmed)
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-$160.93M-$1.64N/AN/AN/A-253.30%-38.17%-28.42%5/1/2024 (Estimated)
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$35.15B$16.049.1113.372.4145.26%36.43%15.01%7/18/2024 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$4.71B-$12.41N/AN/AN/A-68.84%-10.23%-7.70%5/2/2024 (Confirmed)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B$0.3670.569.171.143.62%10.88%4.91%5/1/2024 (Confirmed)
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$22.38B$16.3630.2815.981.434.05%26.50%8.60%7/12/2024 (Estimated)

Latest JNJ, UNH, PFE, MRNA, EBS, AZN, and FATE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
Moderna, Inc. stock logo
MRNA
Moderna
-$3.36N/A+$3.36N/AN/AN/A  
5/1/2024N/A
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
-$3.65N/A+$3.65N/AN/AN/A  
5/1/2024N/A
Pfizer Inc. stock logo
PFE
Pfizer
$0.57N/A-$0.57N/AN/AN/A  
4/16/2024Q1 24
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.64$2.71+$0.07$3.22$21.39 billion$21.38 billion    
4/16/2024Q1 24
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$6.63$6.91+$0.28$15.35$99.23 billion$99.80 billion    
3/6/2024Q4 2023
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
-$0.33-$0.77-$0.44-$0.59$247.63 million$276.60 million      
2/26/202412/31/2023
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-$0.57-$0.45+$0.12-$0.45$0.85 million$1.68 million    
2/22/2024Q4 2023
Moderna, Inc. stock logo
MRNA
Moderna
-$0.78$0.55+$1.33$0.55$2.53 billion$2.80 billion    
2/8/202412/31/2023
AstraZeneca PLC stock logo
AZN
AstraZeneca
$0.74$0.73-$0.01$1.15$12.07 billion$12.02 billion    
1/30/202412/31/2023
Pfizer Inc. stock logo
PFE
Pfizer
-$0.19$0.10+$0.29$0.80$14.37 billion$14.25 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.932.57%+1.18%94.61%1 Years
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
N/AN/AN/AN/AN/A
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
N/AN/AN/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$4.963.39%+5.70%30.92%63 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.61%+2.57%466.67%15 Years
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$7.521.52%+14.71%45.97%14 Years

Latest JNJ, UNH, PFE, MRNA, EBS, AZN, and FATE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2024
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.426.4%5/9/20245/10/20246/14/2024
4/16/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.243.36%5/20/20245/21/20246/4/2024
2/8/2024
AstraZeneca PLC stock logo
AZN
AstraZeneca
Semi-Annual$0.96502.3%2/22/20242/23/20243/25/2024
2/23/2024
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
quarterly$1.881.43%3/8/20243/11/20243/19/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AstraZeneca PLC stock logo
AZN
AstraZeneca
0.57
0.82
0.64
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
0.69
1.04
0.54
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
N/A
8.48
8.48
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.38
1.16
0.91
Moderna, Inc. stock logo
MRNA
Moderna
0.04
3.42
3.36
Pfizer Inc. stock logo
PFE
Pfizer
0.69
0.91
0.69
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
0.69
0.85
0.79

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AstraZeneca PLC stock logo
AZN
AstraZeneca
20.35%
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
78.40%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
97.54%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
87.86%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AstraZeneca PLC stock logo
AZN
AstraZeneca
89,9003.10 billionN/AOptionable
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
1,60052.39 million51.76 millionOptionable
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
181113.82 million108.08 millionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
131,9002.41 billion2.41 billionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,600382.88 million322.77 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.66 billion5.66 billionOptionable
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
440,000920.08 million916.86 millionOptionable

JNJ, UNH, PFE, MRNA, EBS, AZN, and FATE Headlines

SourceHeadline
2,826 Shares in UnitedHealth Group Incorporated (NYSE:UNH) Purchased by Stonebrook Private Inc.2,826 Shares in UnitedHealth Group Incorporated (NYSE:UNH) Purchased by Stonebrook Private Inc.
marketbeat.com - April 28 at 2:53 PM
UnitedHealth Group (NYSE:UNH) Stock Price Down 0%UnitedHealth Group (NYSE:UNH) Stock Price Down 0%
americanbankingnews.com - April 28 at 3:58 AM
PFG Investments LLC Has $6.37 Million Position in UnitedHealth Group Incorporated (NYSE:UNH)PFG Investments LLC Has $6.37 Million Position in UnitedHealth Group Incorporated (NYSE:UNH)
marketbeat.com - April 27 at 9:58 PM
Forget Nvidia, These Unstoppable Stocks Are Better BuysForget Nvidia, These Unstoppable Stocks Are Better Buys
fool.com - April 27 at 11:10 AM
This Healthcare Stock Just Gave Investors 100 Billion Reasons to Buy ItThis Healthcare Stock Just Gave Investors 100 Billion Reasons to Buy It
fool.com - April 27 at 8:45 AM
Markel Group Inc. Acquires 6,000 Shares of UnitedHealth Group Incorporated (NYSE:UNH)Markel Group Inc. Acquires 6,000 Shares of UnitedHealth Group Incorporated (NYSE:UNH)
marketbeat.com - April 27 at 12:59 AM
UnitedHealth Group (NYSE:UNH)  Shares Down 0% UnitedHealth Group (NYSE:UNH) Shares Down 0%
marketbeat.com - April 26 at 6:31 PM
UnitedHealth Group Incorporated (NYSE:UNH) Receives Average Recommendation of "Moderate Buy" from BrokeragesUnitedHealth Group Incorporated (NYSE:UNH) Receives Average Recommendation of "Moderate Buy" from Brokerages
americanbankingnews.com - April 26 at 2:32 AM
Stanley Laman Group Ltd. Lowers Stake in UnitedHealth Group Incorporated (NYSE:UNH)Stanley Laman Group Ltd. Lowers Stake in UnitedHealth Group Incorporated (NYSE:UNH)
marketbeat.com - April 25 at 11:45 PM
UnitedHealth Group says patient health information at risk as a result of Change Healthcare cyberattackUnitedHealth Group says patient health information at risk as a result of Change Healthcare cyberattack
bizjournals.com - April 25 at 6:29 PM
UnitedHealth Group (NYSE:UNH) Trading Up 1.4%UnitedHealth Group (NYSE:UNH) Trading Up 1.4%
marketbeat.com - April 25 at 6:19 PM
Walgreens launches specialty pharmacy unit to compete in new PBM eraWalgreens launches specialty pharmacy unit to compete in new PBM era
finance.yahoo.com - April 25 at 1:29 PM
The Blue-Chip Dip: 3 Safe Stocks to Scoop Up Before They RecoverThe Blue-Chip Dip: 3 Safe Stocks to Scoop Up Before They Recover
investorplace.com - April 25 at 7:00 AM
Tokio Marine Asset Management Co. Ltd. Purchases 2,873 Shares of UnitedHealth Group Incorporated (NYSE:UNH)Tokio Marine Asset Management Co. Ltd. Purchases 2,873 Shares of UnitedHealth Group Incorporated (NYSE:UNH)
marketbeat.com - April 24 at 9:46 PM
UnitedHealth Group Shutting Down Optum Virtual Care Telehealth BusinessUnitedHealth Group Shutting Down Optum Virtual Care Telehealth Business
pymnts.com - April 24 at 8:10 PM
UnitedHealth Group (NYSE:UNH) Stock Price Down 0.8%UnitedHealth Group (NYSE:UNH) Stock Price Down 0.8%
marketbeat.com - April 24 at 4:22 PM
United Health Foundation Announces $2 Million Grant to Native American Connections to Establish Mobile Health InitiativeUnited Health Foundation Announces $2 Million Grant to Native American Connections to Establish Mobile Health Initiative
unitedhealthgroup.com - April 24 at 12:27 PM
The True Cost of Megamergers in Healthcare: Higher PricesThe True Cost of Megamergers in Healthcare: Higher Prices
finance.yahoo.com - April 24 at 12:27 PM
Yousif Capital Management LLC Sells 5,736 Shares of UnitedHealth Group Incorporated (NYSE:UNH)Yousif Capital Management LLC Sells 5,736 Shares of UnitedHealth Group Incorporated (NYSE:UNH)
marketbeat.com - April 23 at 9:37 PM
Here’s Why You Should Hold UnitedHealth Group Incorporated (UNH)Here’s Why You Should Hold UnitedHealth Group Incorporated (UNH)
msn.com - April 23 at 9:25 PM
Sector Update: Health Care Stocks Rise Late AfternoonSector Update: Health Care Stocks Rise Late Afternoon
finance.yahoo.com - April 23 at 9:25 PM
Dividend Growth Stars: 7 Stocks With 10-Year Double-Digit Rate HikesDividend Growth Stars: 7 Stocks With 10-Year Double-Digit Rate Hikes
investorplace.com - April 23 at 4:41 PM
UnitedHealth Group (NYSE:UNH) Stock Price Up 0.1%UnitedHealth Group (NYSE:UNH) Stock Price Up 0.1%
marketbeat.com - April 23 at 2:58 PM
Residents, Community Officials Celebrate Aya Tower in East Point following $24 Million RedevelopmentResidents, Community Officials Celebrate Aya Tower in East Point following $24 Million Redevelopment
businesswire.com - April 23 at 12:00 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

AstraZeneca logo

AstraZeneca

NASDAQ:AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Emergent BioSolutions logo

Emergent BioSolutions

NYSE:EBS
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Fate Therapeutics logo

Fate Therapeutics

NASDAQ:FATE
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Johnson & Johnson logo

Johnson & Johnson

NYSE:JNJ
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Moderna logo

Moderna

NASDAQ:MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
UnitedHealth Group logo

UnitedHealth Group

NYSE:UNH
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities. The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was founded in 1974 and is based in Minnetonka, Minnesota.